Nanobiotix SA
PAR:NANO

Watchlist Manager
Nanobiotix SA Logo
Nanobiotix SA
PAR:NANO
Watchlist
Price: 3.034 EUR -5.25% Market Closed
Market Cap: 143m EUR
Have any thoughts about
Nanobiotix SA?
Write Note

Nanobiotix SA
Net Issuance of Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nanobiotix SA
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
Nanobiotix SA
PAR:NANO
Net Issuance of Debt
-€1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-33%
Valneva SE
PAR:VLA
Net Issuance of Debt
€33.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innate Pharma SA
PAR:IPH
Net Issuance of Debt
-€5.2m
CAGR 3-Years
-74%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Net Issuance of Debt
-€7.3m
CAGR 3-Years
43%
CAGR 5-Years
-36%
CAGR 10-Years
-13%
Inventiva SA
PAR:IVA
Net Issuance of Debt
€20.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Net Issuance of Debt
-€18.2m
CAGR 3-Years
-5%
CAGR 5-Years
-99%
CAGR 10-Years
N/A
No Stocks Found

Nanobiotix SA
Glance View

Market Cap
142.9m EUR
Industry
Biotechnology

Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 100 full-time employees. The company went IPO on 2012-10-29. The firm is engaged in developing nanoparticle technology. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The firm develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives the systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

NANO Intrinsic Value
4.297 EUR
Undervaluation 29%
Intrinsic Value
Price

See Also

What is Nanobiotix SA's Net Issuance of Debt?
Net Issuance of Debt
-1m EUR

Based on the financial report for Jun 30, 2024, Nanobiotix SA's Net Issuance of Debt amounts to -1m EUR.

What is Nanobiotix SA's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 10Y
-33%

Over the last year, the Net Issuance of Debt growth was -31%.

Back to Top